Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, December 20th.
Several other equities research analysts have also recently weighed in on ADAP. TheStreet upgraded Adaptimmune Therapeutics from a “d” rating to a “c” rating in a report on Thursday, November 2nd. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. SunTrust Banks restated a “buy” rating and set a $10.00 price objective on shares of Adaptimmune Therapeutics in a research note on Thursday, October 12th. ValuEngine cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Leerink Swann restated an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics in a research note on Friday, September 8th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Adaptimmune Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $11.58.
Shares of Adaptimmune Therapeutics (NASDAQ ADAP) traded down $0.05 during mid-day trading on Wednesday, hitting $7.81. The company’s stock had a trading volume of 206,134 shares, compared to its average volume of 217,317. Adaptimmune Therapeutics has a twelve month low of $3.88 and a twelve month high of $9.29. The stock has a market cap of $736.38 and a PE ratio of -10.41.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Iguana Healthcare Management LLC purchased a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth $205,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth $182,000. Vident Investment Advisory LLC lifted its stake in shares of Adaptimmune Therapeutics by 3.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 251,145 shares of the biotechnology company’s stock worth $2,057,000 after purchasing an additional 7,610 shares during the last quarter. Graticule Asia Macro Advisors LLC purchased a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth $3,242,000. Finally, OxFORD Asset Management LLP lifted its stake in shares of Adaptimmune Therapeutics by 30.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 10,471 shares during the last quarter. Hedge funds and other institutional investors own 54.24% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/11/adaptimmune-therapeutics-adap-downgraded-to-sell-at-bidaskclub.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.